Compare ZTO & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTO | BDTX |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 171.9M |
| IPO Year | 2016 | 2020 |
| Metric | ZTO | BDTX |
|---|---|---|
| Price | $20.58 | $1.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $23.65 | $9.67 |
| AVG Volume (30 Days) | ★ 1.7M | 487.0K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.01 | N/A |
| Revenue Next Year | $9.12 | N/A |
| P/E Ratio | $21.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.11 | $1.60 |
| 52 Week High | $26.20 | $4.94 |
| Indicator | ZTO | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 41.85 |
| Support Level | N/A | $1.61 |
| Resistance Level | $22.84 | $2.28 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 29.30 | 3.75 |
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 20.1% in 2026. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and a major shareholder with 78.7% voting rights as of March 31, 2026. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around a 9.3% interest.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.